Document is current
Any future updates will be listed below
-
Authors
van Tilburg, Sander J. https://orcid.org/0000-0003-3983-9797
Koçer, Selin
Geissler, Judy
van Rijs, Wouter
Tio-Gillen, Anne P.
Tanck, Michael W. T.
Fokkink, Willem-Jan R.
van Doorn, Pieter A.
Jacobs, Bart C.
Nagelkerke, Sietse Q.
Huizinga, Ruth
-
Funding
Funding for this research was provided by:
Prinses Beatrix Spierfonds (W.OR19-24)
- License Information
-
More Information
Article History
Received: 13 December 2024
Revised: 11 June 2025
Accepted: 16 June 2025
First Online: 1 July 2025
Declarations
:
: Sander van Tilburg: Nothing to disclose. Selin Koçer: Nothing to disclose. Judy Geissler: Nothing to disclose. Wouter van Rijs: Nothing to disclose. Anne Tio-Gillen: Nothing to disclose. Michael Tanck: Nothing to disclose. Willem-Jan Fokkink: Nothing to disclose. Pieter van Doorn: Received research grants from Prinses Beatrix Spierfonds, The Netherlands Organisation for Health Research and Development (ZonMW), Sanquin Blood Supply, Takeda, and Grifols. All grants and fees were paid to his institution. Bart Jacobs: Received research grants for work outside the current study from Baxalta, Grifols, CSL-Behring, Annexon, Hansa Biopharma, Roche, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International, and Horizon 2020 and consultancy fees from Roche for activities outside the current study. All grants and fees were paid to his institution. He is the chair of the Steering Committee of the International GBS Outcome Study (IGOS). Sietse Nagelkerke: Nothing to disclose. Ruth Huizinga: Reports grants from the GBS/CIDP Foundation International, NIH and the PANDIA collaboration project co-funded by BÜHLMANN Laboratories AG and the PPP Allowance made available by Health ~ Holland, Top Sector Life Sciences & Health, to Prinses Beatrix Spierfonds to stimulate public–private partnerships under project number LSHM23017-SGF.
